TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma

Purpose - - The role of TP53 mutations in the tumorigenesis of sporadic medulloblastoma (MB) and the value of TP53 mutation status as a prognostic marker are not yet definitely elucidated. A recent report identified TP53 mutations in MB as an adverse prognostic marker. Hence, the current study was...

Full description

Saved in:
Bibliographic Details
Main Authors: Pfaff, Elke (Author) , Remke, Marc (Author) , Sturm, Dominik (Author) , Benner, Axel (Author) , Witt, Hendrik (Author) , Milde, Till (Author) , Bueren, André von (Author) , Wittmann, Andrea (Author) , Schöttler, Anna (Author) , Jorch, Norbert (Author) , Graf, Norbert (Author) , Kulozik, Andreas (Author) , Witt, Olaf (Author) , Scheurlen, Wolfram (Author) , Deimling, Andreas von (Author) , Rutkowski, Stefan (Author) , Taylor, Michael D. (Author) , Tabori, Uri (Author) , Lichter, Peter (Author) , Korshunov, Andrey (Author) , Pfister, Stefan (Author)
Format: Article (Journal)
Language:English
Published: November 08, 2010
In: Journal of clinical oncology
Year: 2010, Volume: 28, Issue: 35, Pages: 5188-5196
ISSN:1527-7755
DOI:10.1200/JCO.2010.31.1670
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.2010.31.1670
Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.2010.31.1670
Get full text
Author Notes:Elke Pfaff, Marc Remke, Dominik Sturm, Axel Benner, Hendrik Witt, Till Milde, André O. von Bueren, Andrea Wittmann, Anna Schöttler, Norbert Jorch, Norbert Graf, Andreas E. Kulozik, Olaf Witt, Wolfram Scheurlen, Andreas von Deimling, Stefan Rutkowski, Michael D. Taylor, Uri Tabori, Peter Lichter, Andrey Korshunov, and Stefan M. Pfister

MARC

LEADER 00000caa a2200000 c 4500
001 1843803240
003 DE-627
005 20250415000230.0
007 cr uuu---uuuuu
008 230428s2010 xx |||||o 00| ||eng c
024 7 |a 10.1200/JCO.2010.31.1670  |2 doi 
035 |a (DE-627)1843803240 
035 |a (DE-599)KXP1843803240 
035 |a (OCoLC)1389806233 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Pfaff, Elke  |d 1985-  |e VerfasserIn  |0 (DE-588)1037262174  |0 (DE-627)755739728  |0 (DE-576)39127614X  |4 aut 
245 1 0 |a TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma  |c Elke Pfaff, Marc Remke, Dominik Sturm, Axel Benner, Hendrik Witt, Till Milde, André O. von Bueren, Andrea Wittmann, Anna Schöttler, Norbert Jorch, Norbert Graf, Andreas E. Kulozik, Olaf Witt, Wolfram Scheurlen, Andreas von Deimling, Stefan Rutkowski, Michael D. Taylor, Uri Tabori, Peter Lichter, Andrey Korshunov, and Stefan M. Pfister 
264 1 |c November 08, 2010 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 28.04.2023 
520 |a Purpose - - The role of TP53 mutations in the tumorigenesis of sporadic medulloblastoma (MB) and the value of TP53 mutation status as a prognostic marker are not yet definitely elucidated. A recent report identified TP53 mutations in MB as an adverse prognostic marker. Hence, the current study was conducted to validate the prognostic role of TP53 mutation in MB and to understand its contribution to tumorigenesis. - - Methods - - A comprehensive genetic analysis of 310 MB samples was performed by screening for TP53 mutations and further relating the TP53 mutation status to p53 immunostaining, cytogenetic aberrations, and clinical variables. - - Results - - Mutation analysis of TP53 revealed mutations in 21 (6.8%) of 310 samples. Germline TP53 mutations were found in two patients with a history suggestive of a hereditary cancer syndrome. TP53 mutation status was not associated with unfavorable prognosis (P = .63) and was not linked to 17p allelic loss but was over-represented in the prognostically favorable WNT subgroup of MB as defined by CTNNB1 mutation (seven of 35 TP53-mutated tumors v 14 of 271 TP53 wild-type tumors; P = .005) and in tumors carrying high-level MYCN amplification (seven of 21 TP53-mutated tumors v 14 of 282 TP53 wild-type tumors; P = .001). - - Conclusion - - The contradictory results in the recent literature concerning the prognostic value of TP53 mutation might be explained by different frequencies of WNT MBs, different frequencies of patients with Li-Fraumeni syndrome, and different cumulative doses of alkylating drugs applied in these studies. 
700 1 |a Remke, Marc  |d 1981-  |e VerfasserIn  |0 (DE-588)140368787  |0 (DE-627)618255133  |0 (DE-576)316618179  |4 aut 
700 1 |a Sturm, Dominik  |d 1983-  |e VerfasserIn  |0 (DE-588)1035550709  |0 (DE-627)749549165  |0 (DE-576)383282144  |4 aut 
700 1 |a Benner, Axel  |d 1959-  |e VerfasserIn  |0 (DE-588)106584686X  |0 (DE-627)81687221X  |0 (DE-576)425536602  |4 aut 
700 1 |a Witt, Hendrik  |e VerfasserIn  |0 (DE-588)1043235884  |0 (DE-627)770439373  |0 (DE-576)394592085  |4 aut 
700 1 |a Milde, Till  |d 1973-  |e VerfasserIn  |0 (DE-588)1038311837  |0 (DE-627)75711234X  |0 (DE-576)39229334X  |4 aut 
700 1 |8 1\p  |a Bueren, André von  |e VerfasserIn  |0 (DE-588)1027425445  |0 (DE-627)729125017  |0 (DE-576)373208502  |4 aut 
700 1 |a Wittmann, Andrea  |e VerfasserIn  |4 aut 
700 1 |a Schöttler, Anna  |e VerfasserIn  |4 aut 
700 1 |a Jorch, Norbert  |e VerfasserIn  |4 aut 
700 1 |a Graf, Norbert  |e VerfasserIn  |4 aut 
700 1 |a Kulozik, Andreas  |d 1959-  |e VerfasserIn  |0 (DE-588)1025736567  |0 (DE-627)723892032  |0 (DE-576)167091638  |4 aut 
700 1 |a Witt, Olaf  |d 1965-  |e VerfasserIn  |0 (DE-588)17275030X  |0 (DE-627)697681750  |0 (DE-576)133607410  |4 aut 
700 1 |a Scheurlen, Wolfram  |e VerfasserIn  |4 aut 
700 1 |a Deimling, Andreas von  |d 1959-  |e VerfasserIn  |0 (DE-588)103034115X  |0 (DE-627)735093946  |0 (DE-576)378138065  |4 aut 
700 1 |a Rutkowski, Stefan  |e VerfasserIn  |4 aut 
700 1 |a Taylor, Michael D.  |e VerfasserIn  |4 aut 
700 1 |a Tabori, Uri  |e VerfasserIn  |4 aut 
700 1 |a Lichter, Peter  |d 1957-  |e VerfasserIn  |0 (DE-588)1096366282  |0 (DE-627)856749915  |0 (DE-576)468019049  |4 aut 
700 1 |a Korshunov, Andrey  |e VerfasserIn  |4 aut 
700 1 |a Pfister, Stefan  |d 1974-  |e VerfasserIn  |0 (DE-588)123850215  |0 (DE-627)706450930  |0 (DE-576)293908400  |4 aut 
773 0 8 |i Enthalten in  |t Journal of clinical oncology  |d Alexandria, Va. : American Society of Clinical Oncology, 1983  |g 28(2010), 35 vom: Nov., Seite 5188-5196  |h Online-Ressource  |w (DE-627)313116962  |w (DE-600)2005181-5  |w (DE-576)090887018  |x 1527-7755  |7 nnas  |a TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma 
773 1 8 |g volume:28  |g year:2010  |g number:35  |g month:11  |g pages:5188-5196  |g extent:9  |a TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma 
856 4 0 |u https://doi.org/10.1200/JCO.2010.31.1670  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://ascopubs.org/doi/10.1200/JCO.2010.31.1670  |x Verlag  |z lizenzpflichtig  |3 Volltext 
883 |8 1\p  |a cgwrk  |d 20250403  |q DE-101  |u https://d-nb.info/provenance/plan#cgwrk 
951 |a AR 
992 |a 20230428 
993 |a Article 
994 |a 2023 
998 |g 123850215  |a Pfister, Stefan  |m 123850215:Pfister, Stefan  |d 910000  |d 910500  |e 910000PP123850215  |e 910500PP123850215  |k 0/910000/  |k 1/910000/910500/  |p 21  |y j 
998 |g 1096366282  |a Lichter, Peter  |m 1096366282:Lichter, Peter  |d 50000  |e 50000PL1096366282  |k 0/50000/  |p 19 
998 |g 103034115X  |a Deimling, Andreas von  |m 103034115X:Deimling, Andreas von  |d 910000  |d 912000  |e 910000PD103034115X  |e 912000PD103034115X  |k 0/910000/  |k 1/910000/912000/  |p 15 
998 |g 17275030X  |a Witt, Olaf  |m 17275030X:Witt, Olaf  |d 910000  |d 910500  |e 910000PW17275030X  |e 910500PW17275030X  |k 0/910000/  |k 1/910000/910500/  |p 13 
998 |g 1025736567  |a Kulozik, Andreas  |m 1025736567:Kulozik, Andreas  |d 910000  |d 910500  |e 910000PK1025736567  |e 910500PK1025736567  |k 0/910000/  |k 1/910000/910500/  |p 12 
998 |g 1038311837  |a Milde, Till  |m 1038311837:Milde, Till  |d 910000  |d 910500  |e 910000PM1038311837  |e 910500PM1038311837  |k 0/910000/  |k 1/910000/910500/  |p 6 
998 |g 1043235884  |a Witt, Hendrik  |m 1043235884:Witt, Hendrik  |d 910000  |d 910500  |e 910000PW1043235884  |e 910500PW1043235884  |k 0/910000/  |k 1/910000/910500/  |p 5 
998 |g 106584686X  |a Benner, Axel  |m 106584686X:Benner, Axel  |d 50000  |e 50000PB106584686X  |k 0/50000/  |p 4 
998 |g 1035550709  |a Sturm, Dominik  |m 1035550709:Sturm, Dominik  |p 3 
998 |g 140368787  |a Remke, Marc  |m 140368787:Remke, Marc  |d 50000  |e 50000PR140368787  |k 0/50000/  |p 2 
998 |g 1037262174  |a Pfaff, Elke  |m 1037262174:Pfaff, Elke  |p 1  |x j 
999 |a KXP-PPN1843803240  |e 4316020358 
BIB |a Y 
SER |a journal 
JSO |a {"origin":[{"dateIssuedDisp":"November 08, 2010","dateIssuedKey":"2010"}],"relHost":[{"recId":"313116962","title":[{"title_sort":"Journal of clinical oncology","title":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal"}],"id":{"issn":["1527-7755"],"eki":["313116962"],"zdb":["2005181-5"]},"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"1983-","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","dateIssuedKey":"1983"}],"language":["eng"],"part":{"volume":"28","year":"2010","text":"28(2010), 35 vom: Nov., Seite 5188-5196","issue":"35","extent":"9","pages":"5188-5196"},"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"pubHistory":["1.1983 -"],"corporate":[{"role":"isb","display":"American Society of Clinical Oncology"}],"disp":"TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastomaJournal of clinical oncology","type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}]}],"id":{"doi":["10.1200/JCO.2010.31.1670"],"eki":["1843803240"]},"physDesc":[{"extent":"9 S."}],"title":[{"title_sort":"TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma","title":"TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 28.04.2023"],"recId":"1843803240","person":[{"given":"Elke","display":"Pfaff, Elke","role":"aut","family":"Pfaff"},{"family":"Remke","role":"aut","given":"Marc","display":"Remke, Marc"},{"display":"Sturm, Dominik","given":"Dominik","role":"aut","family":"Sturm"},{"family":"Benner","role":"aut","given":"Axel","display":"Benner, Axel"},{"family":"Witt","role":"aut","display":"Witt, Hendrik","given":"Hendrik"},{"family":"Milde","role":"aut","display":"Milde, Till","given":"Till"},{"role":"aut","family":"Bueren","display":"Bueren, André von","given":"André von"},{"family":"Wittmann","role":"aut","given":"Andrea","display":"Wittmann, Andrea"},{"family":"Schöttler","role":"aut","display":"Schöttler, Anna","given":"Anna"},{"role":"aut","family":"Jorch","given":"Norbert","display":"Jorch, Norbert"},{"role":"aut","family":"Graf","display":"Graf, Norbert","given":"Norbert"},{"family":"Kulozik","role":"aut","given":"Andreas","display":"Kulozik, Andreas"},{"given":"Olaf","display":"Witt, Olaf","role":"aut","family":"Witt"},{"given":"Wolfram","display":"Scheurlen, Wolfram","family":"Scheurlen","role":"aut"},{"display":"Deimling, Andreas von","given":"Andreas von","family":"Deimling","role":"aut"},{"role":"aut","family":"Rutkowski","given":"Stefan","display":"Rutkowski, Stefan"},{"given":"Michael D.","display":"Taylor, Michael D.","family":"Taylor","role":"aut"},{"given":"Uri","display":"Tabori, Uri","family":"Tabori","role":"aut"},{"display":"Lichter, Peter","given":"Peter","family":"Lichter","role":"aut"},{"family":"Korshunov","role":"aut","display":"Korshunov, Andrey","given":"Andrey"},{"family":"Pfister","role":"aut","display":"Pfister, Stefan","given":"Stefan"}],"name":{"displayForm":["Elke Pfaff, Marc Remke, Dominik Sturm, Axel Benner, Hendrik Witt, Till Milde, André O. von Bueren, Andrea Wittmann, Anna Schöttler, Norbert Jorch, Norbert Graf, Andreas E. Kulozik, Olaf Witt, Wolfram Scheurlen, Andreas von Deimling, Stefan Rutkowski, Michael D. Taylor, Uri Tabori, Peter Lichter, Andrey Korshunov, and Stefan M. Pfister"]},"language":["eng"]} 
SRT |a PFAFFELKERTP53MUTATI0820